IMNM Q1 2021 Earnings — Immunome, Inc. Revenue & Financial Results | Market Cap Arena

IMNMImmunome, Inc.

$2B

Q1 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$4M

Net Income

-$4M

EPS (Diluted)

$-0.37

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$4M

Free Cash Flow

-$4M

Stock-Based Comp.

$325,000

Balance Sheet

Total Assets

$43M

Total Liabilities

$5M

Stockholders' Equity

$38M

Cash & Equivalents

$36M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$4M	-$3M	-46.8%
Net Income	-$4M	-$3M	-45.6%